Public Company News
U Power Signs Initial €540,000 Sales Agreement with Polestar Energy for the Purchase and Deployment of Twenty Battery-Swapping Electric Vans in Southern Europe
U Power Expects Additional Orders for Up to 2,000 Electric Vans and Compatible Battery-Swapping Stations In the Future SHANGHAI, Oct. 21, 2025 /PRNewswire/ -- U Power Limited (Nasdaq: UCAR) (the "Company" or "U Power"), a provider of AI-powered solutions for next-generation energy grids and inte...
Recurrent Energy Closes $825 Million in Project Financing for Arizona Energy Projects
Recurrent Energy's latest solar and energy storage projects support Arizona
Public Service's record power needs
KITCHENER, ON, Oct. 21, 2025 /PRNewswire/ -- Recurrent Energy
HanchorBio Secures US Patent for Innovative SIRPα/CD47 Fusion Protein HCB101
TAIPEI and SHANGHAI and SAN FRANCISCO, Oct. 21, 2025 /PRNewswire/ -- HanchorBio today announced that its proprietary HCB101, a SIRPα/CD47 fusion protein candidate, has been officially granted a US patent (Patent No. 12,447,195) by the United States Patent and Trademark Office (USPTO). Titled"E...
CAAS Introduces Rear-Wheel Active Steering Technology to Upper Mass-Market EVs in China
WUHAN, China, Oct. 21, 2025 /PRNewswire/ -- China Automotive Systems, Inc. (Nasdaq: CAAS) ("CAAS" or the "Company"), a leading power steering components and systems supplier inChina, today announced that with the rapid growth of automotive technological innovation, CAAS' subsidiary, Jingzhou Heng...
Baidu to Report Third Quarter 2025 Financial Results on Nov 18, 2025
BEIJING, Oct. 21, 2025 /PRNewswire/ -- Baidu, Inc. (Nasdaq: BIDU; HKEX: 9888 (HKD Counter) and 89888 (RMB Counter)) ("Baidu" or the "Company"), a leading AI company with strong Internet foundation, today announced that it will report its financial results for the Third Quarter 2025 endedSeptember...
Google AI Breakthrough Highlights Silmitasertib (CX-4945) as a Novel Pathway in Cancer Immunotherapy
TAIPEI and SAN DIEGO, Oct. 20, 2025 /PRNewswire/ -- Senhwa Biosciences's investigational new drug Silmitasertib (CX-4945) was recently featured in an official post by Google DeepMind, following a major breakthrough by the tech giant's biological artificial intelligence (AI) system. DeepMind re...
SK Biopharmaceuticals Launches Joint Venture with Eurofarma for AI-based Epilepsy Management Platform
SK Biopharmaceuticals forms a joint venture, Mentis Care, to develop an integrated epilepsy care ecosystem through AI-driven platform commercialization. SEOUL, South Korea, Oct. 20, 2025 /PRNewswire/ -- SK Biopharmaceuticals, Co., Ltd., a biotech company focusing on research, development, and co...
Eason Technology Limited Received NYSE American Non-Compliance Letter
HONG KONG, Oct. 20, 2025 /PRNewswire/ -- Eason Technology Limited ("Eason
Technology" or the "Company") (NYSE:DXF
The Generation Essentials Group Reports on Half Year Performance with a ~160% Increase in Revenue
* TGE Achieved ~160% Increase in Revenue * Hospitality arm's revenue increased by over 60% * Total Net Income Surged over 70% to US$61.0 million (non-GAAP adjusted) * Total Assets amounted to US$1.25 billion (US$25.7/share) * Net asset value amounted to US$841 million (US$17.3/share) PARIS...
HanchorBio Showcases Pipeline Momentum with HCB101 and HCB301 Data Across Five Major Oncology Meetings in Q4 2025
Presentations highlight HCB101's differentiated profile and introduce first preclinical data from HCB301, underscoring HanchorBio's innovation in next-generation immunotherapies TAIPEI, SHANGHAI and SAN FRANCISCO, Oct. 20, 2025 /PRNewswire/ -- HanchorBio Inc. (TPEx: 7827), a global clinical-stag...
HD Hyundai Vice Chairman Chung Kisun Promoted to Chairman
SEOUL, South Korea, Oct. 20, 2025 /PRNewswire/ -- HD Hyundai announced that
Executive Vice ChairmanChung Kisun has been promoted to Chairman in its latest
executive appointments.
Zeekr Group to Report Third Quarter 2025 Financial Results on November 17, 2025
HANGZHOU, China, Oct. 20, 2025 /PRNewswire/ -- ZEEKR Intelligent Technology Holding Limited ("Zeekr Group" or the "Company") (NYSE: ZK), the world's leading premium new energy vehicle group, today announced that it will report its unaudited financial results for the third quarter endedSeptember 3...
CARsgen Presents Preliminary Results on Satri-cel for Adjuvant Therapy of Pancreatic Cancer at ESMO Congress 2025
SHANGHAI, Oct. 20, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the research results of the Phase Ib registrational clinical trial of satricabtagene autoleucel ("satri-cel", CT041)...
ESMO 2025: CStone Discloses Phase I Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)
SUZHOU, China, Oct. 19, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key disease areas, today announced the first disclosure...
Clover Appoints Nicholas Jackson, Ph.D., as President of Global R&D and Alliances
SHANGHAI, Oct. 19, 2025 /PRNewswire/ -- Clover Biopharmaceuticals, Ltd.
Significant OS Benefit with Cadonilimab in First-Line Advanced Gastric Cancer: Final Analysis of COMPASSION-15 Presented at ESMO 2025
HONG KONG, Oct. 19, 2025 /PRNewswire/ -- On October 19, 2025, Akeso (9926.HK) announced the final analysis results from the COMPASSION-15/AK104-302 study at the 2025 European Society of Medical Oncology Congress (ESMO 2025) . COMPASSION-15 is a Phase III clinical trial evaluating cadonilimab, Ak...
HARMONi-6 Data: mPFS 11.14 Months (HR=0.6, P<0.0001) Simultaneously Released at ESMO and in The Lancet
* Ivonescimab plus chemotherapy demonstrated a median PFS of 11.14 months, PFS HR=0.60, P < 0.0001. * The absolute difference in median PFS between the two groups was 4.24 months (ΔPFS = 4.24 months), indicating significantly prolonged progression-free survival with ivonescimab combination th...
Case Report | Preliminary Clinical Data of CARsgen's Allogeneic BCMA CAR-T Product CT0596 for the Treatment of Primary Plasma Cell Leukemia
SHANGHAI, Oct. 19, 2025 /PRNewswire/ -- Primary plasma cell leukemia (pPCL) is a rare and highly aggressive plasma cell malignancy, often associated with complex genetic abnormalities. There is currently no standard treatment regimens, and conventional therapies for multiple myeloma are typically...
PINTEC's Subsidiary ZIITECH Makes Its Debut at Tech Week Singapore 2025
BEIJING, Oct. 17, 2025 /PRNewswire/ -- Pintec Technology Holdings Limited (Nasdaq: PT) ("PINTEC" or the "Company"), a leading technology platform committed to enabling innovative financial and digital solutions for businesses worldwide, today announced that its subsidiary ZIITECH PTY LTD ("ZIITEC...
CLPS Incorporation Reports Financial Results for the Second Half and Full Year of Fiscal 2025
HONG KONG, Oct. 17, 2025 /PRNewswire/ -- CLPS Incorporation (the "Company" or "CLPS") (Nasdaq: CLPS), today announced its financial results for the six months and full year of fiscal 2025 ended June 30, 2025. During this fiscal year, we faced a significant challenge when our long-standing and hi...
Week's Top Stories
Most Reposted
Agoda Begins Limited Public Beta of New AI Assistant That Turns Travel Ideas into Bookable Trips
[Picked up by 287 media titles]
2026-09-15 11:00Futurise Impact Report 2025 Highlights Progress in Regulatory Innovation Future-Ready Technologies
[Picked up by 272 media titles]
2026-09-09 13:26Novo Holdings invests in ForYou Medical to support global growth in advanced wound care manufacturing
[Picked up by 264 media titles]
2026-09-10 15:00New ASEAN Study Reveals Businesses Are Rethinking Hiring and Investment as Growth Priorities Shift
[Picked up by 260 media titles]
2026-09-10 07:45CLP Power Hosts AESIEAP CEO Conference 2026 in Hong Kong
[Picked up by 256 media titles]
2026-09-15 19:07